Publisher
Springer Nature Switzerland
Reference26 articles.
1. ICH Q6B: Specifications – Test Procedures and Acceptance Criteria for Biotechnological/Biological Products (March 1999); database.ich.org/sites/default/files/Q6B%20Guideline.pdf
2. Valliere-Douglas J, Marzilli L, et al. Biopharmaceutical industry practices for sequence variant analyses of recombinant protein therapeutics. PDA J Pharm Sci Technol. 2019;73:622–34.
3. EMA Medicines: European Public Assessment Report: Lunsumio (Mosunetuzumab) EPAR (April 2022); www.ema.europa.eu/en/medicines/human/EPAR/lunsumio
4. Randhawa, Z. L., Witkowska, H. E., et. al, Incorporation of Norleucine at Methionine Positions in Recombinant Human Macrophage Colony Stimulating Factor (M-CSF, 4-153) Expressed in E. Coli: Structural Analysis; Biochemistry (1994) 33(14): 4352–4362.
5. Karbalaei M, Rezaee SA, Farsiani H. Pichia pastoris: a highly successful expression system for optimal synthesis of heterologous proteins. J Cell Physiol. 2020;235(9):5867–81.